On September 19, Shenyang Cell Valley officially opened. Concurrently, the "Presentation of Achievements in the Construction of Shenyang Biomedical New Technology Clinical Translation Platform and Shenyang Cell Valley Medical-Industry-Academia-Research-Application Cooperation Exchange Meeting" was held at Shenyang Cell Valley.

With the theme "Pooling Efforts for Clinical Translation, Jointly Building a Cell Industry Innovation Ecosystem," the conference brought together nearly 60 guests from medical institutions, universities and research institutes, industry associations, the life and health industry, and related enterprises in Shenyang and Liaoning Province. Shi Yuanyuan, Chairman of the Cell Valley Group headquarters; Wang Jianxun, Chief Scientist; Tang Xiaomeng, Deputy General Manager; Wei Zheng, Administrative Director; and Sun Rui, Head of Marketing, also traveled from Shenzhen to Shenyang to attend the conference. The meeting featured in-depth exchanges on topics including clinical research and translation of emerging biomedical technologies, development of the cell and gene therapy industry, innovation in anti-aging and the life and health industry, and medical-industry-academia-research collaboration.

The official opening of Shenyang Cell Valley marks a new stage of development for the Cell Valley Group's strategic layout in Northeast China and establishes a new specialized carrier for Shenyang to further aggregate cell and gene therapy technologies, clinical resources, research achievements, and industrial elements.

Taking the Opening as a New Starting Point to Build a Clinical Translation Platform for Emerging Biomedical Technologies

In his address at the conference, Professor Shi Yuanyuan, Chairman of the Cell Valley Group, stated that the completion and opening of Shenyang Cell Valley is the result of the joint efforts of all parties and, more importantly, a new starting point. Recently, leaders from Tiexi District, the Economic Development Zone, Shenyang City, and Liaoning Province have successively visited Shenyang Cell Valley for inspection and guidance, greatly encouraging all Cell Valley employees. He noted that in recent years, frontier life science technologies such as cell therapy, gene therapy, and immunotherapy have developed rapidly, and biomedicine is undergoing an important period of evolution from traditional drug treatment toward more precise and personalized treatment models. Particularly against the backdrop of the formal implementation of the Regulations on the Administration of Clinical Research and Clinical Translational Application of Emerging Biomedical Technologies, China's emerging biomedical technologies have entered a new institutional environment and development opportunities in moving from scientific research to standardized clinical research and clinical translation.

Facing this new industrial stage, Shenyang Cell Valley will base itself in Liaoning, take root in Shenyang, and rely on the industrial foundation of Tiexi District and the Shenyang Life and Health City. It will fully leverage the Cell Valley Group's technological accumulation in cell preparation, gene delivery, quality control, clinical research support, and achievement translation to further serve medical institutions, universities and research institutes, and clinical expert teams in Liaoning Province.

Shi Yuanyuan stated that what Cell Valley hopes to do is not merely to build an enterprise, but more importantly to build an industrial infrastructure and clinical translation platform that can truly serve scientists, clinicians, and hospitals. It strives to open up the key chain of "basic research – technology development – process translation – clinical research – industrial application," enabling more innovative achievements from hospitals and universities to move from the laboratory to the clinic and from papers to products.

Both "Aiming High" and "Standing Grounded"

In his address, Shi Yuanyuan also specifically discussed Cell Valley's industrial philosophy.

The life science industry must both look up at the stars and keep its feet on the ground; it must both "aim high" and "stand grounded."

"Aiming high" means targeting major diseases such as tumors and immune system disorders and continuously pursuing frontier technological innovation in cell therapy, gene therapy, and beyond.

Currently, the Cell Valley Group continues to build out its layout around cell therapy directions including CAR-T, CAR-NK, NK, γδT, and TCR-T, as well as underlying technology platforms including retroviral vectors, lentiviral vectors, AAV, eVLP, LNP, and gene editing. It hopes to explore new solutions for the treatment of major diseases through innovations with genuine technological barriers and clinical value.

"Standing grounded" means that technological innovation must ultimately serve human health and social needs.

Therefore, while laying out major disease treatment technologies, Cell Valley is also actively expanding into industry directions related to broader health, health management, and consumer health, including skincare serums and freeze-dried masks, so that life science technologies are not only reflected in laboratories and hospitals but can also gradually enter broader health consumption scenarios.

One end connects to the forefront of life sciences, and the other connects to the real health needs of ordinary people; one end pursues long-term, high-barrier technological innovation, and the other develops products capable of generating industrial and market value. This is also the development path that Shenyang Cell Valley hopes to adhere to in the future.

Gathering Hospital, University, and Industrial Resources to Promote Deep Integration of Medical-Industry-Academia-Research

Gao Mingyu, Deputy Director of the Education, Science, Health and Sports Committee of the Liaoning Provincial Committee of the Chinese People's Political Consultative Conference, former Party Secretary of Shenyang Pharmaceutical University, and Dean of the Anti-Aging Research Institute, delivered an address at the meeting.

Gao Mingyu shared insights on anti-aging technology R&D and industrial innovation. He stated that the development of the life and health industry and the anti-aging industry cannot be separated from collaboration among university research, clinical medicine, and industrial forces. Universities possess advantages in basic research and talent; hospitals possess clinical needs and clinical resources; and enterprises undertake important functions in engineering, industrialization, and achievement translation.

Only when all parties truly establish long-term, stable collaborative mechanisms can research achievements be accelerated into real productive forces, jointly promoting the high-quality development of Liaoning's life and health industry and cell industry.

Experts and guests from units including the First Affiliated Hospital of China Medical University, the Central Hospital Affiliated to Shenyang Medical College, Liaoning Cancer Hospital, Liaoning Provincial People's Hospital, Shenyang Anorectal Hospital, Shenyang Emergency Center, Shenyang Pharmaceutical University, the Peking University Institute of Urban Soft Power, the Liaoning Provincial Immunology Society, and the Liaoning Provincial Biotechnology Association participated in the event.

Representatives from China-Germany Park Development and Construction Group Co., Ltd., along with enterprises from the fields of life and health, science and technology, industrial investment, and equipment manufacturing, also attended the conference to explore cooperation opportunities for the future development of Shenyang's cell industry together with clinical, research, and industry parties.

Visiting Shenyang Cell Valley On-Site to Showcase Platform Development Achievements

Following the speeches, attending guests conducted an on-site tour of the Shenyang Cell Valley corporate exhibition hall and standardized laboratories.

Through the smart exhibition hall, technology achievement displays, and on-site laboratory visits, guests gained a further understanding of the Cell Valley Group's national layout, core technology system, and Shenyang Cell Valley's development in cell preparation, storage, biochemical testing, R&D, and clinical translation support.

From laboratory construction to industrial platform development, from scientific research technology to clinical needs, and from the hospital side to the industry side, Shenyang Cell Valley is gradually forming an important carrier connecting multi-party resources.

At the event, attending hospital experts, university researchers, and enterprise representatives also engaged in in-depth exchanges on clinical project cooperation, research achievement translation, platform co-development, and the development of the life and health industry.

Taking Root in Liaoning to Drive More Innovative Achievements Toward Clinical Application

Shenyang possesses university research resources including China Medical University and Shenyang Pharmaceutical University, as well as numerous high-level medical institutions, providing a solid foundation in medicine, pharmacy, clinical research, and the biopharmaceutical industry.

Taking this official opening as a new starting point, Shenyang Cell Valley will further strengthen cooperation with top-tier tertiary hospitals, universities and research institutes, clinical experts, and industrial enterprises in Liaoning Province.

Going forward, Shenyang Cell Valley will adhere to clinical demand as the driving force, technology platforms as the foundation, medical-industry-academia-research collaboration as the pathway, and achievement translation as the goal. It will continuously enhance its capabilities in cell preparation, quality control, technology R&D, and clinical research services, actively undertake innovative projects from hospitals and research teams, and provide professional support for emerging biomedical technologies moving from the research stage to the clinical stage.

At the same time, the Cell Valley Group will fully leverage the synergistic role among its platforms in Shenzhen, Beijing, Shenyang, and other regions, introducing more advanced technologies, outstanding scientist projects, and industrial resources, and gradually building a life and health innovation ecosystem spanning research, clinical application, and industry in Northeast China.

The opening of Shenyang Cell Valley is not merely the inauguration of a new space, but also signifies the official launch of a new medical-industry-academia-research cooperation platform.

Starting from Shenyang, based in Liaoning, and serving Northeast China, Shenyang Cell Valley will persist in doing long-term and valuable work, adhering to science, quality, and clinical value orientation, and striving to make more innovative technologies truly serve doctors, hospitals, patients, and social needs—contributing new strength to the high-quality development of the life and health industry and the cell and gene therapy industry in Liaoning and the broader Northeast region.